TIXiMED Funding, Profile & Why It Matters

Overview

TIXiMED is a clinical-stage pharmaceutical company developing TIX100, an oral small-molecule inhibitor of thioredoxin-interacting protein (TXNIP), intended as a disease-modifying therapy for Type 1 diabetes by protecting insulin-producing beta cells. Founded in 2021 as a UAB spinout by Dr. Anath Shalev (UAB Comprehensive Diabetes Center) and Michael Goodrich of Birmingham’s First Avenue Ventures, the company is headquartered in Birmingham, AL. In December 2024 TIXiMED announced a $2.65M program-related investment (loan) from The Leona M. and Harry B. Helmsley Charitable Trust to advance first-in-human trials; the company later reported successful completion of a Phase 1 single ascending dose study and additional Helmsley PRI support for Phase 1b work.

Why TIXiMED is interesting

Most T1D care is insulin management; TIXiMED is pushing a disease-modifying oral bet on TXNIP inhibition from UAB Comprehensive Diabetes Center science — with Helmsley Charitable Trust PRIs totaling multi-million non-dilutive capital and First Avenue Ventures co-founder involvement.

Product & use cases

TIX100 is TIXiMED’s lead oral TXNIP inhibitor; the company holds exclusive license rights to related composition-of-matter and method-of-use IP and is advancing human clinical studies.

People with Type 1 diabetes seeking disease-modifying options beyond insulin alone (investigational)
Clinical development of oral beta-cell–protective therapy
Potential broader metabolic indications explored in pre-clinical models (company-stated)

Key facts

Helmsley Charitable Trust PRI (Dec 2024): $2.65M loan to initiate clinical trials of TIX100
Oral TXNIP inhibitor (TIX100) for Type 1 diabetes; FDA IND path into first-in-human studies
UAB spinout founded 2021; co-founded with First Avenue Ventures’ Michael Goodrich
Phase 1 SAD study completed; Phase 1b MAD work and expanded Helmsley PRI reported

Fundraising history

Program-related investment (loan)

2024-12 $2.65M

Helmsley Charitable Trust (lead)

Source: https://www.businesswire.com/news/home/20241219802666/en/TIXiMED-Announces-a-%242.65M-Program-Related-Investment-from-the-Helmsley-Charitable-Trust-to-Initiate-Clinical-Trials-of-Its-Novel-Oral-Therapy-for-Beta-Cell-Survival-and-Function

Investors in our directory

Funds linked from TIXiMED's profile — open a fund page for stage focus and related deal articles.

First Avenue Ventures

Competitive landscape

Edge: Specific oral TXNIP inhibition grounded in UAB academic discovery and human TXNIP biology — a distinct mechanism versus insulin delivery devices or general immuno-modulators.

Insulin pumps / CGM ecosystems incumbent

Standard of care manages glucose; does not target TXNIP biology.
Disease-modifying T1D immunotherapies (e.g., teplizumab class) adjacent

Different mechanism and patient timing; not oral TXNIP inhibitors.

Industries

Biotech & Life Sciences Healthtech

FAQs about TIXiMED

Practical answers founders, operators, and investors typically search for.

TIXiMED develops TIX100, an investigational oral TXNIP inhibitor aimed at protecting beta cells in Type 1 diabetes.

Birmingham, AL.

Yes — founded in 2021 from research led by Dr. Anath Shalev at UAB’s Comprehensive Diabetes Center.

Michael Goodrich of First Avenue Ventures (/fund/first-avenue-ventures).

A $2.65M program-related investment (loan) announced December 2024 to support first-in-human trials; TIXiMED later announced an expanded Helmsley PRI for Phase 1b/tox work.

Clinical-stage biotech (stage tagged other); private company.

Thioredoxin-interacting protein — elevated in diabetes and linked to beta-cell death and dysfunction; TIX100 is designed to inhibit it.

No — investigational. Company reported FDA IND clearance and completion of a Phase 1 SAD study, with further clinical work ongoing.

Insulin treats glucose; TIXiMED’s thesis is oral disease modification via TXNIP biology, not replacing insulin devices today.

Venture Capital Tracker

TIXiMED

Stage

Status

Coverage